Neurological Conditions (Other) - MND, Spinal Cord Injury, Stroke

An early feasibility study of the safety of the Stentrode™ device in participants with loss of motor function due to paralysis from spinal cord injury, motor neuron disease, stroke, muscular dystrophy or loss of limbs.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Liver Related Disease

Primary biliary cholangitis (PBC) is a chronic disease in which the bile ducts in your liver are slowly destroyed. Human studies have shown that seladelpar may be useful for treating the signs and symptoms of PBC and lower alkaline phosphatase (AP) level and decrease itching.

The purpose of this research is to evaluate the safety and effectiveness of an investigational drug, seladelpar, in treating patients with PBC.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Cancer - Liver

The purpose of this study is to find out if Cabozantinib in combination with Atezolizumab is effective in treating liver cancer (hepatocellular carcinoma) compared to Sorafenib alone in people who have not received prior treatment.

This study will also examine how well people with liver cancer who have not received prior treatment tolerate Cabozantinib alone, and how well it works in treating their cancer.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Cancer - Liver

The immune system is the body’s natural defense against disease. The immune system sends types of cells called T cells throughout the body to detect and fight infections and diseases, including cancers. One way the immune system controls the activity of T cells is through a process called the PD-1 pathway. Some cancer cells hide from T-cell attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Immunotherapy drugs work by blocking the PD-1 pathway helping the immune system detect and fight cancer cells.

CBT-501, one of the experimental treatments in this research project, also blocks the PD-1 pathway.

This study involves research about CBT-101, a substance that blocks a type of enzyme called a kinase. Human cells have many different kinases, and they help control important functions, such as cell signaling, metabolism, division, and survival.

The combination of CBT-501 with CBT-101 is a new immunotherapy approach to see if CBT-101 possibly enhances the effectiveness of CBT-501 in liver tumours. CBT-501 and CBT-101 have demonstrated anti-tumour effects in animal studies. They are currently being studied in humans in other research studies.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Multiple sclerosis

We are seeking to examine the effectiveness of a tailored cognitive behaviour (CBT) therapy based psychological intervention for the treatment of depression in people newly diagnosed with multiple sclerosis. CBT is a type of "talk therapy" that helps people learn new skills targeting their thinking and behaviour often used for the treatment of depression, anxiety.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Healthy Volunteers

Cognition relates to an individual’s thinking, learning and memory processes, and can change over time. Memory and cognitive changes in people with MS can be part of the relapse cycles in RRMS or can be gradual in onset and possibly progressive over time. In both these cases a sensitive and reliable test to measure cognitive function would be of use to detect cognitive change, monitor progress, and to identify significant cognitive impairment as early as possible so that treatment can be adjusted. The study that we are conducting will determine whether new computer-based tests can be used easily in a MS clinic and whether the testing can also be reliably done at home.

We would like to collect cognitive performance data over time from both people with MS and people without MS. This is important as comparing the results between people with and without MS helps us to understand how accurate the test is.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Diabetes (Type 1)

This study will test whether a new tablet can help to treat diabetic kidney disease. The study will last for 56 weeks, and participants will be allocated to receive either the new tablet or placebo. There will be 10 study visits.

Anticipated date enrolment will close: June 2020

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Diabetes (Type 2)

We are seeking volunteers for the SURPASS-4 study which is a clinical trial investigating the safety and effectiveness of tirzepatide when taken once weekly compared to insulin taken once daily in people with type 2 diabetes and increased cardiovascular risk.

The primary purpose of the study aims to address the following questions:

  • Whether tirzepatide can help study participants with type 2 diabetes
  • The safety of tirzepatide and any side effects when taken
  • How much tirzepatide should be given to study participants
  • How tirzepatide compares to insulin glargine

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4